Mr. Zachary Goldenberg reports

HARMONY ACQUISITIONS ANNOUNCES PROPOSED QUALIFYING TRANSACTION WITH VIMY PHARMACEUTICALS

Harmony Acquisitions Corp. and Vimy Pharmaceuticals Inc. (Vimy Pharma) have entered into a non-binding letter of intent (LOI) dated Aug. 4, 2026, pursuant to which Harmony and Vimy Pharma intend to complete a business combination or other similarly structured transaction that will constitute a reverse takeover of Harmony.

It is intended that the transaction will be an arm's-length qualifying transaction for Harmony, as such term is defined in Policy 2.4 of the corporate finance manual of the TSX Venture Exchange. Trading of the common shares of the company has been halted and it is expected that the common shares will remain halted until completion of the transaction. The parties intend to rename the resulting issuer Vimy Pharmaceuticals Corp. upon completion of the transaction.

In connection with the transaction, Vimy Pharma has entered into an agreement with Beacon Securities Inc. with respect to a concurrent financing of Vimy Pharma, pursuant to which Beacon shall act as lead agent and sole bookrunner.

A comprehensive news release will be issued by Harmony and Vimy Pharma setting out the terms of the transaction, which shall include information about Harmony upon closing of the transaction and more information regarding the concurrent financing.

Overview of Vimy Pharma

Vimy Pharma is a Canadian pharmaceutical company focused on improving access to affordable medicines while supporting domestic pharmaceutical manufacturing capacity and long-term Canadian supply resilience. Vimy Pharma is advancing a portfolio of essential medicines as generic pharmaceutical products intended to support patients, health care systems and Canada's life sciences sector.

A strategic priority for Vimy Pharma is expanding access to innovative therapies through the development of generic alternatives to popular medicines. By combining domestic production with cost-efficient manufacturing and regulatory expertise, Vimy Pharma seeks to provide affordable treatment options while contributing to Canada's pharmaceutical sovereignty.

Earlier this year, Vimy Pharma completed one of its development programs and filed an abbreviated new drug submission (ANDS) with Health Canada, which has been found acceptable for review, for a generic version of Ozempic (semaglutide injection), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes. Ozempic has been the highest-earning prescription medicine in Canada for the past four years with combined sales of semaglutide injection medicines in Canada totalling $3.5-billion in 2025, growing at 31 per cent over the previous year (1). Vimy Pharma undertook its development work in Canada and will carry out its commercial production domestically, with Canadian partners. Additionally, Vimy Pharma has established partnerships to support the many large and growing international markets for injectable semaglutide.

Vimy Pharma is led by an experienced management team, including former executives from Novo Nordisk A/S, with broader organizational expertise spanning pharmaceutical development, manufacturing, regulatory affairs, commercialization and capital markets. Vimy Pharma is committed to long-term value creation through disciplined execution, innovation and the development of a sustainable domestic pharmaceutical ecosystem that serves patients, health care providers and government partners, and supports Canadian pharmaceutical supply resilience and access to medicines.

About Harmony Acquisitions Corp.

Harmony was incorporated under the Business Corporations Act (British Columbia) on May 7, 2021, and is a capital pool company listed on the TSX Venture Exchange.

Advisers

Wildeboer Dellelce LLP is acting as legal counsel to Vimy Pharma in connection with the transaction and Dentons Canada LLP is acting as legal counsel to Harmony.

(1) Chris Hannay, "Canada will be a launching pad in the global race for generic Ozempic," The Globe and Mail (Jan. 30, 2026; updated Jan. 31, 2026).

We seek Safe Harbor.